Carotid ultrasound to identify head and neck cancer survivors with high cardiovascular risk after radiation therapy: rationale and design of a prospective, cross-sectional pilot study.
Ryan T Hughes, Anna C Snavely, Emily V Dressler, Charles H Tegeler, Chandylen L Nightingale, Cristina M Furdui, David R Soto Pantoja, Thomas C Register, Kathryn E Weaver, Glenn J Lesser
{"title":"Carotid ultrasound to identify head and neck cancer survivors with high cardiovascular risk after radiation therapy: rationale and design of a prospective, cross-sectional pilot study.","authors":"Ryan T Hughes, Anna C Snavely, Emily V Dressler, Charles H Tegeler, Chandylen L Nightingale, Cristina M Furdui, David R Soto Pantoja, Thomas C Register, Kathryn E Weaver, Glenn J Lesser","doi":"10.1080/14796694.2024.2386927","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Radiation therapy is an integral component of treatment that can predispose to carotid artery stenosis (CAS) and increase the risk of cerebrovascular events for head and neck cancer survivors. The utility of screening for CAS with carotid ultrasound in asymptomatic head and neck cancer survivors is unclear.<b>Methods:</b> In this prospective, cross-sectional pilot study, 60 patients who have no evidence of cancer at least 2 years from completion of RT will undergo screening carotid ultrasound to identify patients with high risk of cardiovascular events.<b>Results:</b> Outcomes will include clinically significant CAS, carotid intima-media thickness, acceptability/feasibility of screening, barriers to care and preliminary data on changes to medical management because of screening. Correlative multi-omics analyses will examine biomarkers of CAS after radiation therapy.<b>Conclusion:</b> The results of this study will provide valuable data on the prevalence of CAS and preliminary patient-centered data that will inform the design of a future large-scale, multi-site clinical trial.<b>Clinical Trial Registration:</b> NCT05490875 (ClinicalTrials.gov).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520544/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2386927","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Radiation therapy is an integral component of treatment that can predispose to carotid artery stenosis (CAS) and increase the risk of cerebrovascular events for head and neck cancer survivors. The utility of screening for CAS with carotid ultrasound in asymptomatic head and neck cancer survivors is unclear.Methods: In this prospective, cross-sectional pilot study, 60 patients who have no evidence of cancer at least 2 years from completion of RT will undergo screening carotid ultrasound to identify patients with high risk of cardiovascular events.Results: Outcomes will include clinically significant CAS, carotid intima-media thickness, acceptability/feasibility of screening, barriers to care and preliminary data on changes to medical management because of screening. Correlative multi-omics analyses will examine biomarkers of CAS after radiation therapy.Conclusion: The results of this study will provide valuable data on the prevalence of CAS and preliminary patient-centered data that will inform the design of a future large-scale, multi-site clinical trial.Clinical Trial Registration: NCT05490875 (ClinicalTrials.gov).
背景:放疗是头颈癌治疗的一个组成部分,它可能导致颈动脉狭窄(CAS),并增加头颈癌幸存者发生脑血管事件的风险。在无症状的头颈癌幸存者中使用颈动脉超声筛查 CAS 的效用尚不明确:在这项前瞻性、横断面试点研究中,60 名在 RT 结束后至少 2 年没有癌症证据的患者将接受颈动脉超声筛查,以确定心血管事件高风险患者:结果将包括具有临床意义的 CAS、颈动脉内膜中层厚度、筛查的可接受性/可行性、护理障碍以及因筛查而改变医疗管理的初步数据。相关的多组学分析将检查放疗后 CAS 的生物标志物:这项研究的结果将提供有关 CAS 患病率的宝贵数据和以患者为中心的初步数据,为未来大规模、多地点临床试验的设计提供参考:临床试验注册:NCT05490875(ClinicalTrials.gov)。
期刊介绍:
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.